Cargando…

Immune Thrombocytopenic Purpura and Intracerebral Hemorrhage, Incidence, and Mortality

Introduction: Intracerebral hemorrhage (ICH) is a devastating complication of immune thrombocytopenic purpura (ITP). Using a large database, we sought to determine its incidence and mortality. Methods: We used a de-identified database (TriNetX) to gather information on patients with ITP with subsequ...

Descripción completa

Detalles Bibliográficos
Autores principales: Hallan, David R, Simion, Christopher, Sciscent, Bao Y, Lee, John, Rizk, Elias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128758/
https://www.ncbi.nlm.nih.gov/pubmed/35637831
http://dx.doi.org/10.7759/cureus.24447
_version_ 1784712611914317824
author Hallan, David R
Simion, Christopher
Sciscent, Bao Y
Lee, John
Rizk, Elias
author_facet Hallan, David R
Simion, Christopher
Sciscent, Bao Y
Lee, John
Rizk, Elias
author_sort Hallan, David R
collection PubMed
description Introduction: Intracerebral hemorrhage (ICH) is a devastating complication of immune thrombocytopenic purpura (ITP). Using a large database, we sought to determine its incidence and mortality. Methods: We used a de-identified database (TriNetX) to gather information on patients with ITP with subsequent ICH (cohort 1), propensity score-matched with patients with ITP and no ICH (cohort 2). Primary endpoint was mortality, with secondary endpoints of percutaneous endoscopic gastrostomy (PEG) placement, craniotomy, palliative care encounters, intensive care unit (ICU) management, seizure, falls, pulmonary embolism (PE), myocardial infarction (MI), deep venous thrombosis (DVT), ischemic stroke (IS), and other venous embolism and thrombosis (VTE). Results: Incidence of ICH in patients with ITP was 1.540% in all ages, and 0.774% in those under age 18. After matching, 942 patients from each cohort were identified. Mean age was 58.3 years versus 61.2 years in cohort 1 and 2, respectively. Mortality rate was 34.076% vs. 20.17% (p <0.0001, OR 2.046 with 95% CI 1.661,2.520) at five years. Thirty-day survival was 83.46% vs. 95.17% (p<0.0001), and 365-day survival 68.59% vs. 85.33% (p<0.0001). PEG placement was seen in 21 (2.229%) patients in cohort 1, and less than 10 patients (<1.062%) in cohort 2 (p<0.0464). 2.442% vs. 0% underwent craniotomy (p<0.0001), palliative care was involved in 15.711% vs. 7.962% (p<0.0001), ICU care was seen in 27.389% vs. 11.783% (p<0.0001), with a mean ICU stay of 8.075 vs. 5.812 days (p=0.0537). 6.582% vs. 3.715% had PE (p=0.0049), 7.643% vs. 7.113% experienced MI (p=0.6595), 9.236% vs. 4.883% had DVTs (p=0.0002), 23.673% vs. 5.732% had seizures (p<0.0001), 9.023% vs. 6.582% suffered falls (p=0.0482), 7.537% vs. 3.503% suffered IS (p<0.0001), and 15.074% vs. 8.174% experienced other VTE (p<0.0001). Conclusion: ICH occurs in approximately 1.54% of ITP patients, and is associated with a 34% mortality rate, increased PEG tube placement rates, palliative care involvement, ICU care, craniotomy, PE, IS, DVT, seizures, and falls. 
format Online
Article
Text
id pubmed-9128758
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-91287582022-05-29 Immune Thrombocytopenic Purpura and Intracerebral Hemorrhage, Incidence, and Mortality Hallan, David R Simion, Christopher Sciscent, Bao Y Lee, John Rizk, Elias Cureus Neurosurgery Introduction: Intracerebral hemorrhage (ICH) is a devastating complication of immune thrombocytopenic purpura (ITP). Using a large database, we sought to determine its incidence and mortality. Methods: We used a de-identified database (TriNetX) to gather information on patients with ITP with subsequent ICH (cohort 1), propensity score-matched with patients with ITP and no ICH (cohort 2). Primary endpoint was mortality, with secondary endpoints of percutaneous endoscopic gastrostomy (PEG) placement, craniotomy, palliative care encounters, intensive care unit (ICU) management, seizure, falls, pulmonary embolism (PE), myocardial infarction (MI), deep venous thrombosis (DVT), ischemic stroke (IS), and other venous embolism and thrombosis (VTE). Results: Incidence of ICH in patients with ITP was 1.540% in all ages, and 0.774% in those under age 18. After matching, 942 patients from each cohort were identified. Mean age was 58.3 years versus 61.2 years in cohort 1 and 2, respectively. Mortality rate was 34.076% vs. 20.17% (p <0.0001, OR 2.046 with 95% CI 1.661,2.520) at five years. Thirty-day survival was 83.46% vs. 95.17% (p<0.0001), and 365-day survival 68.59% vs. 85.33% (p<0.0001). PEG placement was seen in 21 (2.229%) patients in cohort 1, and less than 10 patients (<1.062%) in cohort 2 (p<0.0464). 2.442% vs. 0% underwent craniotomy (p<0.0001), palliative care was involved in 15.711% vs. 7.962% (p<0.0001), ICU care was seen in 27.389% vs. 11.783% (p<0.0001), with a mean ICU stay of 8.075 vs. 5.812 days (p=0.0537). 6.582% vs. 3.715% had PE (p=0.0049), 7.643% vs. 7.113% experienced MI (p=0.6595), 9.236% vs. 4.883% had DVTs (p=0.0002), 23.673% vs. 5.732% had seizures (p<0.0001), 9.023% vs. 6.582% suffered falls (p=0.0482), 7.537% vs. 3.503% suffered IS (p<0.0001), and 15.074% vs. 8.174% experienced other VTE (p<0.0001). Conclusion: ICH occurs in approximately 1.54% of ITP patients, and is associated with a 34% mortality rate, increased PEG tube placement rates, palliative care involvement, ICU care, craniotomy, PE, IS, DVT, seizures, and falls.  Cureus 2022-04-24 /pmc/articles/PMC9128758/ /pubmed/35637831 http://dx.doi.org/10.7759/cureus.24447 Text en Copyright © 2022, Hallan et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Neurosurgery
Hallan, David R
Simion, Christopher
Sciscent, Bao Y
Lee, John
Rizk, Elias
Immune Thrombocytopenic Purpura and Intracerebral Hemorrhage, Incidence, and Mortality
title Immune Thrombocytopenic Purpura and Intracerebral Hemorrhage, Incidence, and Mortality
title_full Immune Thrombocytopenic Purpura and Intracerebral Hemorrhage, Incidence, and Mortality
title_fullStr Immune Thrombocytopenic Purpura and Intracerebral Hemorrhage, Incidence, and Mortality
title_full_unstemmed Immune Thrombocytopenic Purpura and Intracerebral Hemorrhage, Incidence, and Mortality
title_short Immune Thrombocytopenic Purpura and Intracerebral Hemorrhage, Incidence, and Mortality
title_sort immune thrombocytopenic purpura and intracerebral hemorrhage, incidence, and mortality
topic Neurosurgery
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128758/
https://www.ncbi.nlm.nih.gov/pubmed/35637831
http://dx.doi.org/10.7759/cureus.24447
work_keys_str_mv AT hallandavidr immunethrombocytopenicpurpuraandintracerebralhemorrhageincidenceandmortality
AT simionchristopher immunethrombocytopenicpurpuraandintracerebralhemorrhageincidenceandmortality
AT sciscentbaoy immunethrombocytopenicpurpuraandintracerebralhemorrhageincidenceandmortality
AT leejohn immunethrombocytopenicpurpuraandintracerebralhemorrhageincidenceandmortality
AT rizkelias immunethrombocytopenicpurpuraandintracerebralhemorrhageincidenceandmortality